Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares OutstandingShares OutstandingShort-Term Debt issuancesShort-Term Debt repayments
Ratios

China Pharma Holdings (CPHI) Receivables - Net (2016 - 2025)

China Pharma Holdings filings provide 16 years of Receivables - Net readings, the most recent being $254435.0 for Q4 2025.

  • On a quarterly basis, Receivables - Net fell 98.16% to $254435.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $254435.0, a 98.16% decrease, with the full-year FY2025 number at $254435.0, down 98.16% from a year prior.
  • Receivables - Net hit $254435.0 in Q4 2025 for China Pharma Holdings, down from $294514.0 in the prior quarter.
  • In the past five years, Receivables - Net ranged from a high of $14.1 million in Q1 2024 to a low of $44444.0 in Q3 2022.
  • Median Receivables - Net over the past 5 years was $414162.5 (2021), compared with a mean of $3.1 million.
  • Biggest five-year swings in Receivables - Net: surged 15115.77% in 2024 and later crashed 98.16% in 2025.
  • China Pharma Holdings' Receivables - Net stood at $714475.0 in 2021, then plummeted by 41.0% to $421531.0 in 2022, then rose by 19.67% to $504448.0 in 2023, then skyrocketed by 2639.49% to $13.8 million in 2024, then crashed by 98.16% to $254435.0 in 2025.
  • The last three reported values for Receivables - Net were $254435.0 (Q4 2025), $294514.0 (Q3 2025), and $268793.0 (Q2 2025) per Business Quant data.